Not a good buy right now for an impatient investor: pre-market is sharply weaker (-8.81%) and momentum is deteriorating (MACD histogram negative and expanding).
The bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) suggests the bigger-picture trend hasn’t fully broken, but near-term price action is currently bearish and below the pivot (6.639).
Without Intellectia buy signals today (AI Stock Picker / SwingMax), there’s no high-conviction timing edge to justify buying into current weakness.
Trend/Momentum: MACD histogram is -0.096 (below 0) and negatively expanding → bearish momentum is strengthening.
RSI: RSI_6 at 29.497 → near-oversold/weak territory; can support a short-term bounce, but does not override the bearish MACD.
Moving averages: SMA_5 > SMA_20 > SMA_200 → longer trend still technically constructive, but current weakness suggests risk of a pullback within that uptrend.
Key levels: Pivot 6.639 (price 6.505 is below it = near-term bearish). Support S1 6.234 then S2 5.984. Resistance R1 7.044 then R2 7.294.
Pattern-based odds (provided): ~80% chance of modest gains (+1.18% next day / +2.27% next week / +5.31% next month), but this conflicts with today’s negative momentum and pre-market hit—so probabilities look less actionable right now.
Positive Catalysts
can attract dip-buyers if selling pressure fades.
Neutral/Negative Catalysts
Pre-market drop of -8.81% signals immediate selling pressure and poor near-term sentiment.
MACD bearish and worsening (negative, expanding) increases the odds of further downside before any sustainable bounce.
Financial snapshot shows extremely weak operating picture (revenue listed as 0; large net loss), which can cap upside and raise downside risk.
Trading trends: hedge funds and insiders show neutral activity—no supportive accumulation signal.
No congress trading data; no external “influential buyer” signal to lean on.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: reported as 0 (up 0.00% YoY) → effectively no top-line support in the snapshot provided.
Net income: -13.736M ("up" 566.15% YoY) → still a very large loss despite YoY improvement.
EPS: -7.92 ("up" 513.95% YoY) → still deeply negative.
Gross margin: reported as 0 (up 0.00% YoY) → consistent with the revenue snapshot and not supportive of a bullish fundamental case.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price-target changes were provided in the dataset, so there is no observable recent Wall Street upgrade/downgrade trend to support a buy.
Wall Street-style pros (based on available info): potential technical bounce from near-oversold conditions; longer-term MA structure still positive.
Wall Street-style cons: weak/unclear fundamentals in the latest quarter snapshot (revenue shown as 0 and large losses); no catalyst/news; no visible institutional/insider accumulation trend.
Wall Street analysts forecast CLRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLRO is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast CLRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLRO is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
